Scotland first UK nation to routinely offer HIV PrEP along with Psoriasis, MS and CLL treatments

Scotland is set to become the first UK nation to routinely offer HIV pre-exposure prophylaxis to eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada along with four other new therapies to be funded by the NHS. In clinical trials Truvada (emtricitabine/tenofovir disoproxil) was revealed to cut the relative risk of

Continue Reading

GW Pharmaceuticals gains orphan status for rare epilepsy cannabinoid Epidiolex

UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy. The approval follows data from two late-stage trials that showed when Epidiolex was added as an adjunct to patients’ current treatment, there was a significant reduction in the

Continue Reading

New Pfizer antibiotic, Zavicefta launched in UK

Zavicefta has now been launched in the UK to treat serious aerobic Gram-negative infections caused by antibiotic resistant bacteria. The Pfizer drug is a fixed combination of avibactam, a new beta-lactamase inhibitor, and ceftazidime, an antibiotic belonging to the class of third generation cephalosporins which is already approved for use in the EU.

Continue Reading

New specialised treatments cleared for NHS funding

NHS England announces three new specialised treatments are to be made available on the NHS for patients in England after initial rejection for funding back in December. Funding has been now been approved for second allogeneic haematopoietic stem cell transplants (also known as bone marrow transplants), with around 15 patients a year who suffer a

Continue Reading